Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Severe Arteriovenous Malformations
NCT02042326Phase 2Recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2014
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in Arteriovenous Malformation (AVM), sponsored by CHU Amiens-Picardie. Primary endpoint: Treatment efficacy at M12 at 12 months. Started Sep 2014; status: recruiting.
02
Drugs
sirolimus
03
Conditions
Arteriovenous Malformation (AVM)
Beyond the preview
Go deeper on NCT02042326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042326.